LIVE

Sanofi to review its new eczema drug amlitelimab - Meet them in May

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study - Meet them in May

J&J eyes $100B in sales amid gains for cancer, immune drugs - Meet them in May

Alumis soars as TYK2 drug hits mark in psoriasis trials - Meet them in May

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Connect’s Dupixent challenger hits the mark in phase 3 eczema trial

Apogee strengthens case for longer-lasting eczema drug

Annemie Deiteren

Head of Early Clinical & Experimental Therapeutics Sanofi

Thursday 21st May 2026

Strengthening Early Confidence in Dermatology Drug Development: Using Translational Pharmacology Models to Validate Targets Before Patient Trials

11:30 am

Validating inflammatory pathways through translational human pharmacology models, including inducible skin challenge systems that allow early proof-of-mechanism testing before committing to full patient trials
Benchmarking multi-pathway modulation against known therapeutic mechanisms to differentiate biological effects and prioritize the most promising targets for further development
Using early translational pharmacology and experimental therapeutic studies to inform clinical strategy, generating mechanistic evidence that strengthens regulatory discussions and supports progression toward Phase II trials in indications such as HS